Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children

被引：40
作者：
Garg, Millie [1 ]
Leach, Steven T. [1 ]
Coffey, Michael J. [1 ]
Katz, Tamarah [2 ]
Strachan, Roxanne [3 ]
Pang, Tamara [1 ]
Needham, Bronwen. [4 ]
Lui, Kei [1 ,5 ]
Ali, Fathalla [1 ]
Day, Andrew S. [6 ]
Appleton, Laura [6 ]
Moeeni, Vesal [6 ]
Jaffe, Adam [1 ,3 ]
Ooi, Chee Y. [1 ,7 ]
机构：
[1] Univ New S Wales, Sch Womens & Childrens Hlth, Med, Sydney, NSW, Australia
[2] Sydney Childrens Hosp, Dept Nutr & Dietet, High St, Randwick, NSW 2031, Australia
[3] Sydney Childrens Hosp, Dept Resp Med, High St, Randwick, NSW 2031, Australia
[4] Univ Sydney, Sydney Med Program, Camperdown, NSW 2050, Australia
[5] Royal Hosp Women, Dept Newborn Care, Barker St, Randwick, NSW 2031, Australia
[6] Univ Otago, Dept Pediat, 2 Riccarton Ave, Canterbury 8011, New Zealand
[7] Sydney Childrens Hosp, Dept Gastroenterol, High St, Randwick, NSW 2031, Australia
来源：
JOURNAL OF CYSTIC FIBROSIS | 2017年 / 16卷 / 05期
关键词：
Leukocyte L1 antigen complex; Calprotectin; S100; proteins; Cystic fibrosis; Gastrointestinal inflammation; Pediatrics; PANCREATIC-FUNCTION; SMALL-INTESTINE; L1; PROTEIN; GUIDELINES; MICROBIOTA; DYSBIOSIS; INFANTS; MOUSE;
D O I：
10.1016/j.jcf.2017.03.010
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Background: Fecal calprotectin may be used as a non-invasive method to assess the effect of novel therapies on the gut in cystic fibrosis (CF). Method: Stools from CF patients and healthy controls (HC) (0-10 years old) were prospectively collected for evaluation of temporal trends. Results: 130 CF samples (64 subjects) and 114 HC samples (101 subjects) were collected. Overall, fecal calprotectin levels were different in CF patients and HC from 0 to 10 years (P = 0.0002). Fecal calprotectin in CF was significantly lower than HC from 0 to 1 years (P = 0.03) and demonstrated an upward trajectory until 4 years. From >4 to 10 years calprotectin was consistently higher in CF patients compared with HC (P = 0.007). Conclusions: Fecal calprotectin levels in children with CF and HC were age-dependent and had distinct trajectories. Careful interpretation of calprotectin is required if used in drug trials for CF, particularly in children less than 4 years old. (C) 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：631 / 636
页数：6
相关论文
共 30 条
  • [21] Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis
    Manor, Ohad
    Levy, Roie
    Pope, Christopher E.
    Hayden, Hillary S.
    Brittnacher, Mitchell J.
    Carr, Rogan
    Radey, Matthew C.
    Hager, Kyle R.
    Heltshe, Sonya L.
    Ramsey, Bonnie W.
    Miller, Samuel I.
    Hoffman, Lucas R.
    Borenstein, Elhanan
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [22] Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis
    Nielsen, Shaun
    Needham, Bronwen
    Leach, Steven T.
    Day, Andrew S.
    Jaffe, Adam
    Thomas, Torsten
    Ooi, Chee Y.
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [23] Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine
    Norkina, O
    Burnett, TG
    De Lisle, RC
    [J]. INFECTION AND IMMUNITY, 2004, 72 (10) : 6040 - 6049
  • [24] Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children
    Olafsdottir, E
    Aksnes, L
    Fluge, G
    Berstad, A
    [J]. ACTA PAEDIATRICA, 2002, 91 (01) : 45 - 50
  • [25] Fecal Human β-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?
    Ooi, Chee Y.
    Pang, Tamara
    Leach, Steven T.
    Katz, Tamarah
    Day, Andrew S.
    Jaffe, Adam
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (10) : 2946 - 2952
  • [26] Fecal calprotectin in healthy children
    Oord, Tonje
    Hornung, Nete
    [J]. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2014, 74 (03) : 254 - 258
  • [27] Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency
    Smith, Ross C.
    Smith, Sarah F.
    Wilson, Jeremy
    Pearce, Callum
    Wray, Nick
    Vo, Ruth
    Chen, John
    Ooi, Chee Y.
    Oliver, Mark
    Katz, Tamarah
    Turner, Richard
    Nikfarjam, Mehrdad
    Rayner, Christopher
    Horowitz, Michael
    Holtmann, Gerald
    Talley, Nick
    Windsor, John
    Pirola, Ron
    Neale, Rachel
    [J]. PANCREATOLOGY, 2016, 16 (02) : 164 - 180
  • [28] ANTIMICROBIAL ACTIONS OF CALCIUM-BINDING LEUKOCYTE L1 PROTEIN, CALPROTECTIN
    STEINBAKK, M
    NAESSANDRESEN, CF
    LINGAAS, E
    DALE, I
    BRANDTZAEG, P
    FAGERHOL, MK
    [J]. LANCET, 1990, 336 (8718) : 763 - 765
  • [29] VANDEKAMER JH, 1949, J BIOL CHEM, V177, P347
  • [30] Evidence of Intestinal Inflammation in Patients With Cystic Fibrosis
    Werlin, Steven L.
    Benuri-Silbiger, Ishay
    Kerem, Eitan
    Adler, Sam N.
    Goldin, Eran
    Zimmerman, Joseph
    Malka, Netta
    Cohen, Limor
    Armoni, Shoshana
    Yatzkan-Israelit, Yardena
    Bergwerk, Ari
    Aviram, Micha
    Bentur, Lea
    Mussaffi, Huda
    Bjarnasson, Ingvar
    Wilschanski, Michael
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2010, 51 (03) : 304 - 308
123